soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Presented at ACC.25: Among participants with type 2 diabetes and disease, chronic kidney disease, or both, (14 mg) was associated with a lower risk of cardiovascular events than placebo ADA 2025: Oral Semaglutide Demonstrates

This dual attack explains why retatrutide consistently outperforms tirzepatide in head-to-head network meta-analyses

Mounjaro vs Ozempic Mounjaro contains tirzepatide and Ozempic contains semaglutide, with both medications developed to aid blood sugar management in adults with type 2 diabetes

The semaglutide weight management drug market remained anchored to hospital-linked dispensing because initiation often occurred under endocrinology, cardiology, or primary care supervision, especially when comorbid obesity, diabetes, and cardiovascular risk had to be managed together

Providers evaluate potential interactions and risk factors

Air fry or bake salmon 8 min